We are live on
!
Find out more
AbCellera Biologics
ABCL
ABCL
142 hedge funds and large institutions have $682M invested in AbCellera Biologics in 2023 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 46 increasing their positions, 36 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
168% more call options, than puts
Call options by funds: $7.64M | Put options by funds: $2.85M
30% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 20
28% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 36
24% more capital invested
Capital invested by funds: $552M → $682M (+$131M)
3% more funds holding
Funds holding: 138 → 142 (+4)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.33% less ownership
Funds ownership: 41.48% → 41.15% (-0.33%)
Holders
142
Holders Change
+4
Holders Change %
+2.9%
% of All Funds
2.07%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
26
Increased
46
Reduced
36
Closed
20
Calls
$7.64M
Puts
$2.85M
Net Calls
+$4.79M
Net Calls Change
+$702K
Top Buyers
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$9.95M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$8.69M |
| 3 |
BlackRock
New York
|
+$2.3M |
| 4 |
Goldman Sachs
New York
|
+$1.58M |
| 5 |
Two Sigma Advisers
New York
|
+$1.35M |
Top Sellers
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$10M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$3.88M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$3.46M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.31M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.88M |
